Go Pro
NASDAQ:PRFX

PainReform Q4 2025 Earnings Report

PainReform logo
$1.00 -0.03 (-2.91%)
Closing price 04:00 PM Eastern
Extended Trading
$0.99 -0.01 (-1.30%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PainReform EPS Results

Actual EPS
-$0.99
Consensus EPS
-$612.00
Beat/Miss
Beat by +$611.02
One Year Ago EPS
N/A

PainReform Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

PainReform Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

PainReform Earnings Headlines

ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel
See More PainReform Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PainReform? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PainReform and other key companies, straight to your email.

About PainReform

PainReform (NASDAQ:PRFX), a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

View PainReform Profile